Banque Transatlantique SA Takes $369,000 Position in CryoPort, Inc. $CYRX

Key Points

• Banque Transatlantique SA acquired 65,614 shares of CryoPort, Inc. valued at approximately $369,000, indicating growing institutional interest in the company.
• Multiple hedge funds have significantly increased their holdings in CryoPort recently, with SBI Securities raising its position by 548,750.0% and institutional investors now owning 92.90% of the company's stock.
• CryoPort's latest earnings report revealed a missed EPS estimate, reporting ($0.29) versus expectations of ($0.20), despite revenue exceeding estimates at $45.45 million.

Banque Transatlantique SA purchased a new position in shares of CryoPort, Inc. (NASDAQ:CYRX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 65,614 shares of the company's stock, valued at approximately $369,000. Banque Transatlantique SA owned approximately 0.13% of CryoPort at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Millennium Management LLC grew its holdings in shares of CryoPort by 11.0% during the 4th quarter. Millennium Management LLC now owns 4,139,869 shares of the company's stock worth $32,208,000 after purchasing an additional 409,353 shares in the last quarter. Deutsche Bank AG lifted its position in CryoPort by 0.9% during the fourth quarter. Deutsche Bank AG now owns 1,397,121 shares of the company's stock worth $10,870,000 after purchasing an additional 12,864 shares during the period. Dimensional Fund Advisors LP grew its stake in CryoPort by 8.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 850,216 shares of the company's stock worth $6,615,000 after buying an additional 63,301 shares in the last quarter. Silvercrest Asset Management Group LLC increased its holdings in CryoPort by 77.0% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 742,914 shares of the company's stock valued at $5,780,000 after buying an additional 323,216 shares during the period. Finally, Readystate Asset Management LP increased its holdings in CryoPort by 91.6% in the 1st quarter. Readystate Asset Management LP now owns 500,344 shares of the company's stock valued at $3,042,000 after buying an additional 239,153 shares during the period. 92.90% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at CryoPort

In other CryoPort news, Director Ramkumar Mandalam sold 40,728 shares of the business's stock in a transaction that occurred on Tuesday, July 22nd. The shares were sold at an average price of $7.24, for a total transaction of $294,870.72. Following the sale, the director directly owned 92,328 shares of the company's stock, valued at $668,454.72. The trade was a 30.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Robert Stefanovich sold 9,300 shares of the firm's stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $8.67, for a total transaction of $80,631.00. Following the transaction, the chief financial officer directly owned 207,213 shares of the company's stock, valued at $1,796,536.71. The trade was a 4.30% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 435,125 shares of company stock valued at $2,992,628 in the last quarter. 10.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have recently weighed in on CYRX. KeyCorp raised shares of CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 price target for the company in a report on Wednesday, August 6th. BTIG Research cut their target price on CryoPort from $13.00 to $10.00 and set a "buy" rating for the company in a research note on Monday, July 7th. Stephens initiated coverage on CryoPort in a research note on Tuesday, July 22nd. They issued an "overweight" rating and a $13.00 price target on the stock. Leerink Partnrs upgraded CryoPort from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, August 6th. Finally, Leerink Partners raised CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 price objective on the stock in a research note on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, CryoPort has a consensus rating of "Buy" and a consensus target price of $12.00.

CryoPort Price Performance

CYRX stock traded down $0.08 during midday trading on Tuesday, reaching $9.96. 229,673 shares of the stock were exchanged, compared to its average volume of 537,683. CryoPort, Inc. has a 52 week low of $4.58 and a 52 week high of $10.46. The company has a fifty day moving average price of $8.08 and a 200 day moving average price of $6.82. The company has a debt-to-equity ratio of 0.39, a current ratio of 16.24 and a quick ratio of 15.47. The stock has a market capitalization of $498.67 million, a PE ratio of 7.49 and a beta of 1.62.

CryoPort (NASDAQ:CYRX - Get Free Report) last posted its earnings results on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.09). The firm had revenue of $45.45 million during the quarter, compared to the consensus estimate of $41.74 million. CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. CryoPort has set its FY 2025 guidance at EPS. As a group, analysts expect that CryoPort, Inc. will post -0.99 EPS for the current fiscal year.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.